The earnings call presented a generally optimistic outlook with significant progress in key areas such as the development of SER-155, financial management improvements, and strategic partnerships. However, the call also highlighted challenges related to the biotech environment and cash runway limitations, indicating a need for securing additional capital.

Company Guidance

During the Seres Therapeutics second quarter 2025 results and business update call, the company provided guidance on several key metrics and future plans. The Phase II study for SER-155 is designed to enroll approximately 248 participants and aims to prevent bloodstream infections in patients undergoing allo-HSCT, with interim results expected within 12 months of initiation. The company reported a net loss from continuing operations of $19.9 million for Q2 2025, compared to $26.2 million in the same period of 2024. Research and development expenses decreased to $12.9 million, while general and administrative expenses were reduced to $10.3 million. Seres received a $25 million installment from Nestlé in July and had cash and equivalents of $45.4 million as of June 30, 2025, projecting enough funding into the first quarter of 2026. The company continues to explore various business development opportunities, including partnerships and mergers, to secure additional capital for advancing its programs.

Promising SER-155 Progress

The SER-155 Phase Ib study demonstrated a 77% relative risk reduction in bloodstream infections, supporting continued development. The FDA has provided constructive feedback on the Phase II protocol, and the study is expected to be a well-powered, placebo-controlled trial with approximately 248 participants.

Strong Financial Management

Seres reported a net loss reduction from $26.2 million in Q2 2024 to $19.9 million in Q2 2025. Research and development expenses decreased from $15.8 million to $12.9 million, and general and administrative expenses decreased from $13.1 million to $10.3 million year-over-year.

Strategic Partnerships and Capital Acquisition

Seres is actively pursuing partnerships, out-licensing deals, and potential mergers to secure capital and resources for advancing their programs. They are in discussions with multiple parties to achieve this goal.

Advancements in Live Biotherapeutics

At the Digestive Disease Week conference, Seres presented data supporting the potential of live biotherapeutics for treating inflammatory and immune diseases, receiving a poster Distinction Award in the Microbiome and Microbial Therapy subgroup.

Seres Therapeutics (MCRB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MCRB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	0.44 / -	11.6	―	―	―
Aug 06, 2025	2025 (Q2)	-2.49 / -2.27	-4.4	48.41% (+2.13)
May 07, 2025	2025 (Q1)	0.10 / 3.75	-5.4	169.44% (+9.15)
Mar 13, 2025	2024 (Q4)	-3.93 / -1.80	-6.2	70.97% (+4.40)	―
Nov 13, 2024	2024 (Q3)	-1.55 / 11.60	-7.4	256.76% (+19.00)	―
Aug 13, 2024	2024 (Q2)	-5.48 / -4.40	7.2	-161.11% (-11.60)	―
May 08, 2024	2024 (Q1)	-6.83 / -5.40	-11.4	52.63% (+6.00)	―
Mar 05, 2024	2023 (Q4)	-9.93 / -6.20	-10.2	39.22% (+4.00)	―
Nov 02, 2023	2023 (Q3)	-10.03 / -7.40	-9.8	24.49% (+2.40)	―
Aug 08, 2023	2023 (Q2)	10.69 / 7.20	-14	151.43% (+21.20)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MCRB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$14.28	$13.78	-3.50%
May 07, 2025	$8.55	$8.29	-3.04%
Mar 13, 2025	$13.86	$12.77	-7.86%
Nov 13, 2024	$13.28	$11.80	-11.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Seres Therapeutics (MCRB) report earnings?

Seres Therapeutics (MCRB) is schdueled to report earning on Nov 18, 2025, Before Open (Confirmed).

What is Seres Therapeutics (MCRB) earnings time?

Seres Therapeutics (MCRB) earnings time is at Nov 18, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MCRB EPS forecast?

MCRB EPS forecast for the fiscal quarter 2025 (Q3) is 0.44.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing